COX-2 Safety Will Be Discussed By FDA Advisory Committee In Early 2005

FDA will hold an advisory committee in early 2005 to discuss the cardiovascular safety profile of COX-2 inhibitors, Acting Deputy Commissioner of Operations Janet Woodcock, MD, said at an American College of Rheumatology meeting Oct. 18 in San Antonio